Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRAP1 | Q12931 | 5/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 8/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669001 | 1.00 | TRAP1 (0.48) | TRAP1HSP90AA1HSP90B1ABHD6LMNA | |
| SCHEMBL25669033 | 0.90 | HSP90AA1 (0.48) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL30368189 | 0.90 | HSP90AA1 (0.48) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL25243632 | 0.89 | TRAP1 (0.41) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL30301767 | 0.89 | TRAP1 (0.41) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL25211589 | 0.89 | TRAP1 (0.39) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL30301754 | 0.89 | TRAP1 (0.39) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL25214133 | 0.89 | HSP90AA1 (0.41) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL30368666 | 0.89 | HSP90AA1 (0.41) | TRAP1HSP90AA1HSP90B1LMNAHPGD | |
| SCHEMBL30301746 | 0.88 | SLC6A9 (0.39) | TRAP1HSP90AA1HSP90B1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | claimed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| CN-115996907-A | Inhibitors of MLH1 and/or PMS2 for cancer treatment | 奈奥芬莱有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4157463-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | TRAP1 1861/4885HSP90AA1 2502/4885HSP90B1 3336/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | TRAP1 1872/4885HSP90AA1 1915/4885HSP90B1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.